# Imbed Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imbed-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Middleton, US
- Website: www.imbedbio.com
- Total disclosed funding: $3.6M
- Latest round: Series A (Nov 5, 2019)
- Investors on record: 1

## About

Based in Wisconsin, US, and founded in 2012 by Nicholas L. Abbott, Charles J. Czuprynski, and Christopher J. Murphy, Imbed Biosciences, Inc., a.k.a. Imbed Biosciences operates as a medical device company that focuses on developing advanced devices for the treatment of burns, wounds, and soft-tissue repair. In January 2024, Imbed Biosciences, Inc. raised USD 10 million in venture debt funding led by Niterra Corporation Limited, with participation from Pegasus Tech Ventures.

Imbed Biosciences offers Microlyte® Matrix, an antimicrobial synthetic skin substitute for chronic wounds; Surgaflex™, an ultrathin antimicrobial polymer matrix for surgical wounds; and PelashieldAM™, a hydrophilic antimicrobial matrix designed for burn wounds. These products are designed to address the challenges associated with different types of wounds, providing management solutions for healthcare providers.

The company plans to use its proceeds from January 2024 funding for growth strategy, strengthening its market presence, and product development.

## Funding rounds

- Series A, Nov 5, 2019, $2M — WISC Partners
- Seed, Dec 28, 2017, $1.6M — WISC Partners

## Investors

- WISC Partners (https://capitalatlas.ai/funds/wisc-partners) — Seed, Series A